Plain-English translation of NCT07044050 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This is one of the first times this treatment has been tested in people.
This is an early-stage trial testing OT-C001, a treatment made from specially grown immune cells called natural killer cells. The study is designed to find the safest dose and see how well this medication works for people with aggressive lymphoma that has either come back or stopped responding to other treatments.
Many people with aggressive lymphoma eventually run out of standard treatment options, including newer therapies like CAR-T cell therapy. This medication aims to offer a new path forward by harnessing the body's own immune system to fight the cancer.
You likely qualify if…
You likely don't qualify if…
You will first receive a short course of chemotherapy to prepare your body. Then you'll receive weekly doses of the medication for 3 to 6 weeks, along with two supportive drugs (rituximab and IL-2) to help the treatment work better. You'll make regular clinic visits or may be hospitalized at times depending on the study schedule, so your medical team can monitor your safety and how well the treatment is working.
AI-generated summary from trial data · Jun 30, 2026 · Not medical advice
France